A. Kattamis

A. Kattamis, M. Theodoridou, K. Alexandraki, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.

Amanda M Li, A. Kernytsky, D. Altshuler, 2020, The New England journal of medicine.

Mutations and Polymorphisms in Genes Affecting Haemostasis Components in Children with Thromboembolic Events

H. Platokouki, Z. Kapsimali, S. Aronis, 2007, Pathophysiology of Haemostasis and Thrombosis.

Cytogenetically cryptic and fish negative PML/RARA rearrangement in acute promyelocytic leukemia detected by RT-PCR

G. Avgerinou, A. Kattamis, M. Tzanoudaki, 2020, Leukemia & lymphoma.

Optimising management of deferasirox therapy for patients with transfusion‐dependent thalassaemia and lower‐risk myelodysplastic syndromes

A. Taher, A. Kattamis, Y. Aydinok, 2018, European journal of haematology.

Serum Levels of S100b and NSE Proteins in Patients with Non-Transfusion-Dependent Thalassemia as Biomarkers of Brain Ischemia and Cerebral Vasculopathy

I. Papassotiriou, K. Spengos, A. Kattamis, 2017, International journal of molecular sciences.

Evaluation of Intracranial Cerebral Blood Flow Velocities in Splenectomised and Non-Splenectomised Patients with β-Thalassemia Intermedia Using Transcranial Doppler Sonography.

I. Papassotiriou, K. Spengos, A. Kattamis, 2015, In vivo.

Efficacy and safety of deferasirox (Exjade) in patients with transfusion-dependent anemias : 1-year results from the large, prospective, multicenter EPIC study

M. Cappellini, Chi-kong Li, A. El‐Beshlawy, 2008 .

Effect of Deferasirox (Exjade ® ) on Labile Plasma Iron Levels in Heavily Iron-Overloaded Patients with Transfusion-Dependent Anemias Enrolled in the Large-Scale, Prospective 1-Year EPIC Trial

M. Cappellini, A. Taher, A. El‐Beshlawy, 2008 .

Phenotypes of Diamond Blackfan Anemia Patients with RPL35A Haploinsufficiency Due to 3q29 Deletion Compared with RPL35A Single Nucleotide Variants or Small Insertion/Deletions

S. Savage, M. Wlodarski, C. Niemeyer, 2018, Blood.

The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions

E. Neufeld, S. Perrotta, M. Cappellini, 2018, Blood.

The use of oral glucose-lowering agents (GLAs) in β-thalassemia patients with diabetes: Preliminary data from a retrospective study of ICET-A Network

T. Zarei, V. De Sanctis, A. Soliman, 2022, Acta bio-medica : Atenei Parmensis.

Detection of minimal residual disease by mutant p53 immunocytochemistry in acute myelogenous leukemia.

G. Tsangaris, F. Tzortzatou-Stathopoulou, M. Moschovi, 2000, Medical and pediatric oncology.

Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial.

E. Alexopoulou, N. Kelekis, A. Kattamis, 2006, Blood cells, molecules & diseases.

High resolution Chromosomal Microarray Analysis (CMA) enhances the genetic profile of pediatric B-cell Acute Lymphoblastic Leukemia patients.

M. Tzetis, E. Kanavakis, S. Kitsiou-Tzeli, 2019, Leukemia research.

Current approach to iron chelation in children

V. Viprakasit, A. Kattamis, Y. Aydinok, 2014, British journal of haematology.

A novel mutation in the G4.5 (TAZ) gene in a Greek patient with Barth syndrome.

A. Vazeou, A. Kattamis, A. Giannakopoulos, 2009, Blood cells, molecules & diseases.

Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload

D. Pennell, M. Cappellini, Chi-kong Li, 2011, Haematologica.

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study.

S. Rivella, E. Cassinerio, A. Taher, 2018, Blood.

Impact of magnetic resonance imaging on cardiac mortality in thalassemia major

A. Kattamis, G. Chouliaras, C. Fragodimitri, 2011, Journal of magnetic resonance imaging : JMRI.

Survival in a large cohort of Greek patients with transfusion‐dependent beta thalassaemia and mortality ratios compared to the general population

A. Kattamis, G. Chouliaras, C. Fragodimitri, 2011, European journal of haematology.

Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.

I. Papassotiriou, A. Kattamis, C. Kattamis, 2003, Haematologica.

The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets

David C. Jones, F. Westermann, B. Burkhardt, 2021, Cancer discovery.

Iron Chelation Therapy in the Context of the Latest Iron Science

A. Kattamis, 2007 .

Cardiac magnetic resonance in transfusion dependent thalassaemia: assessment of iron load and relationship to left ventricular ejection fraction

S. Mavrogeni, E. Gotsis, A. Kattamis, 2010, British journal of haematology.

Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.

S. Perrotta, M. Cappellini, V. Viprakasit, 2022, The Lancet. Haematology.

Adhesion molecules and high‐sensitivity C‐reactive protein levels in patients with sickle cell beta‐thalassaemia

I. Papassotiriou, P. Makrythanasis, A. Kattamis, 2012, European journal of clinical investigation.

Abnormal myocardial perfusion-fibrosis pattern in sickle cell disease assessed by cardiac magnetic resonance imaging.

S. Mavrogeni, K. Bratis, A. Kattamis, 2013, International journal of cardiology.

PlGF and sFlt‐1 levels in patients with non‐transfusion‐dependent thalassemia: Correlations with markers of iron burden and endothelial dysfunction

I. Papassotiriou, A. Kattamis, F. Apostolakou, 2018, European journal of haematology.

HBeAg-negative hepatitis B in a previously thalassemic patient during immunosuppressive therapy for chronic GVHD

A. Kattamis, S. Kostaridou, V. Ladis, 1998, Bone Marrow Transplantation.

Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia.

M. Cappellini, V. Viprakasit, R. Galanello, 2016, European journal of internal medicine.

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox

M. Cappellini, V. Viprakasit, A. Taher, 2014, European journal of haematology.

Diamond-Blackfan Anemia: 2 Cases With a Twist.

A. Kattamis, P. Delaporta, L. Kossiva, 2020, Journal of pediatric hematology/oncology.

Uncoupling of Bone Turnover may Compromise Skeletal Health of Young Patients With Haemophilia A.

O. Papakonstantinou, A. Kattamis, H. Athanasopoulou, 2021, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

M. Cappellini, Chi-kong Li, S. Thein, 2010, Haematologica.

Approach to the management of β thalassemia major associated osteoporosis - a long-standing relationship revisited

M. Yavropoulou, A. Kattamis, P. Makras, 2022, Acta bio-medica : Atenei Parmensis.

recommendations from an international panel Management of chronic viral hepatitis in patients with thalassemia

G. Brittenham, M. Cappellini, G. Foster, 2013 .

Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel.

G. Brittenham, M. Cappellini, D. Prati, 2010, Blood.

Spontaneous fertility in a male thalassemic patient after allogeneic hematopoietic cell transplantation

N. Iacovidou, A. Kattamis, E. Nana, 2017 .

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.

S. Perrotta, P. Marks, M. Cappellini, 2006, Blood.

Prevalence of glucose dysregulation (GD) in patients with β-thalassemias in different countries: A preliminary ICET-A survey

V. De Sanctis, A. Soliman, S. A. Al Jaouni, 2021, Acta bio-medica : Atenei Parmensis.

Neurologic complications of treatment of childhood acute immune thrombocytopenic purpura with intravenously administered immunoglobulin G.

A. Cohen, A. Kattamis, S. Shankar, 1997, The Journal of pediatrics.

Treatment of thalassemia with hydroxyurea: an indispensable alternative therapy.

A. Kattamis, 2007, Journal of pediatric hematology/oncology.

Electrophysiological assessment for early detection of retinal dysfunction in β-thalassemia major patients

M. Moschos, C. Koutsandrea, K. Chatzistefanou, 2017, Graefe's Archive for Clinical and Experimental Ophthalmology.

Renal function abnormalities and deferasirox.

A. Kattamis, 2019, The Lancet. Child & adolescent health.

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study

M. Cappellini, V. Viprakasit, R. Galanello, 2013, Annals of Hematology.

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.

Vip Viprakasit, Ali T Taher, Maria Domenica Cappellini, 2012, Blood.

Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study

E. Cassinerio, A. Taher, N. Hollaender, 2016 .

The EHA Research Roadmap: Anemias

S. Rivella, D. Girelli, M. Muckenthaler, 2021, HemaSphere.

Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran

M. Cappellini, A. Taher, A. Kattamis, 2006, Thrombosis and Haemostasis.

Revisiting The NTDT vs TDT Classification 10 Years Later.

S. Rivella, M. Cappellini, V. Viprakasit, 2020, American journal of hematology.

Dental late effects of antineoplastic treatment on childhood cancer survivors: radiographic findings.

A. Polychronopoulou, A. Kattamis, K. Seremidi, 2021, International journal of paediatric dentistry.

Sustained response to interferon alpha-2a in thalassemic patients with chronic hepatitis C. A prospective 8-year follow-up study.

L. Nakopoulou, G. Daikos, V. Syriopoulou, 2005, Haematologica.

ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA

V. Viprakasit, S. Sheth, H. Al‐Samkari, 2021, Hematology, Transfusion and Cell Therapy.

Longitudinal Effect of Luspatercept Treatment on Iron Overload and Iron Chelation Therapy (ICT) in Adult Patients (Pts) with β-Thalassemia in the Believe Trial

S. Perrotta, M. Cappellini, V. Viprakasit, 2020 .

P1518: LONG-TERM SAFETY RESULTS OF THE BELIEVE STUDY OF LUSPATERCEPT IN ADULTS WITH ΒETA-THALASSEMIA

M. Cappellini, V. Viprakasit, A. Piga, 2022, HemaSphere.

S270: LONGER-TERM ANALYSIS OF EFFICACY OF LUSPATERCEPT VERSUS PLACEBO IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA ENROLLED IN THE BELIEVE STUDY

M. Cappellini, V. Viprakasit, A. Piga, 2022, HemaSphere.

Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study

M. Pfeilstöcker, S. Gunes, A. Kattamis, 2020, Experimental Hematology & Oncology.

Recommendations regarding splenectomy in hereditary hemolytic anemias

Maria Domenica Cappellini, Achille Iolascon, Antonella Gambale, 2017, Haematologica.

Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials.

M. Cappellini, S. Fucharoen, F. Bonifazi, 2011, Blood cells, molecules & diseases.

Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias

S. Perrotta, A. Taher, A. Kattamis, 2018, Health and Quality of Life Outcomes.

PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum

David C. Jones, M. Kool, E. Papaemmanuil, 2021, Acta Neuropathologica.

Targeted next generation sequencing for the diagnosis of patients with rare congenital anemias

H. Tamary, A. Kattamis, O. Dgany, 2018, European journal of haematology.

S1478951520000449jrv 103..118

G. Chrousos, C. Darviri, A. Kattamis, 2021 .

The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major.

I. Papassotiriou, A. Kattamis, F. Apostolakou, 2006, Haematologica.

High Yield of Pathogenic Germline Mutations Causative or Likely Causative of the Cancer Phenotype in Selected Children with Cancer

A. Wagner, R. Kuiper, M. Ligtenberg, 2018, Clinical Cancer Research.

New lessons from an old gene: complex splicing and a novel cryptic exon in VHL gene cause erythrocytosis and VHL disease Complex genetics in VHL disease and erythrocytosis

R. Redon, K. Schwarz, S. Knight, 2018 .

A prospective study on the epidemiology and clinical significance of viral respiratory infections among pediatric oncology patients

T. Zaoutis, A. Kattamis, V. Papaevangelou, 2019, Pediatric hematology and oncology.

Non-invasive myocardial iron assessment in thalassaemic patients: T2 relaxometry and magnetization transfer ratio measurements

Nickolas Papanikolaou, A. Ghiatas, A. Kattamis, 2000 .

Long-term safety of deferiprone treatment in children from the Mediterranean region with beta-thalassemia major: the DEEP-3 multi-center observational safety study

I. Wong, M. Felisi, D. Bonifazi, 2018, Haematologica.

Genotype-phenotype association and variant characterization in Diamond Blackfan anemia caused by pathogenic variants in RPL35A

S. Savage, M. Wlodarski, L. D. Da Costa, 2020, Haematologica.

Development of a multidisciplinary clinic of neurofibromatosis type 1 and other neurocutaneous disorders in Greece. A 3-year experience

M. Tzetis, A. Kattamis, K. Kosma, 2019, Postgraduate medicine.

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with -thalassemia

M. Cappellini, A. Piga, M. Bejaoui, 2006 .

Deferasirox Safety Profile in Patients with Transfusion-Dependent Anaemias:Results From the Interim Analysis of a Hellenic Study,

M. Athanasiou-Metaxa, E. Voskaridou, A. Kattamis, 2011 .

The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study

S. Sheth, A. Piga, F. Tricta, 2021, British journal of haematology.

Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.

M. Felisi, D. Bonifazi, A. Ceci, 2020, The Lancet. Haematology.

A Concise Review on the Frequency, Major Risk Factors and Surveillance of Hepatocellular Carcinoma (HCC) in β-Thalassemias: Past, Present and Future Perspectives and the ICET-A Experience

V. De Sanctis, A. Soliman, S. A. Al Jaouni, 2020, Mediterranean journal of hematology and infectious diseases.

Pulmonary embolism after snake bite in a child with Diamond-Blackfan anemia.

A. Kattamis, A. Makis, N. Chaliasos, 2011, Journal of pediatric hematology/oncology.

Recommendations for diagnosis and treatment of methemoglobinemia

A. Iolascon, A. Kulozik, R. Russo, 2021, American journal of hematology.

Complex preimplantation genetic diagnosis for beta-thalassaemia, sideroblastic anaemia, and human leukocyte antigen (HLA)-typing

E. Kanavakis, J. Traeger-Synodinos, C. Vrettou, 2016, Systems biology in reproductive medicine.

Diamond–Blackfan anaemia: understanding an old disease

A. Kattamis, 2020, British journal of haematology.

Growth and Development in Children with Thalassaemia Major

A. Kattamis, C. Kattamis, T. Liakopoulou, 1990, Acta paediatrica Scandinavica. Supplement.

Immune reconstitution after autologous purged bone marrow transplantation in children.

D. Campbell, N. Bunin, A. Kattamis, 2000, Journal of pediatric hematology/oncology.

Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease.

R. Redon, K. Schwarz, S. Knight, 2018, Blood.

Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion.

Yves Sznajer, Ana Rita, V. Tasic, 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells

S. Grupp, S. Sheth, M. Cappellini, 2020 .

A Case Series of BCOR Sarcomas With a New Splice Variant of BCOR/CCNB3 Fusion Gene

A. Patereli, K. Stefanaki, M. Liontos, 2020, In Vivo.

Microrna expression signatures predict patient progression and disease outcome in pediatric embryonal central nervous system neoplasms

F. Tzortzatou-Stathopoulou, G. Lambrou, K. Stefanaki, 2014, Journal of Hematology & Oncology.

Assessment of iron distribution between liver, spleen, pancreas, bone marrow, and myocardium by means of R2 relaxometry with MRI in patients with β‐thalassemia major

E. Alexopoulou, E. Efstathopoulos, N. Kelekis, 2009, Journal of magnetic resonance imaging : JMRI.

R2 relaxometry with MRI for the quantification of tissue iron overload in β‐thalassemic patients

Ioannis Seimenis, Efthymia Alexopoulou, Efstathios Efstathopoulos, 2006, Journal of magnetic resonance imaging : JMRI.

Pituitary stalk lesion in a 13-year-old female

N. Patronas, C. Stratakis, M. Lodish, 2014, Journal of pediatric endocrinology & metabolism : JPEM.

International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia.

E. Mejstrikova, O. Hrusak, M. Schrappe, 2018, Blood.

Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia

M. Cappellini, V. Viprakasit, A. Taher, 2015, British journal of haematology.

A review of psychosocial interventions targeting families of children with cancer

G. Chrousos, C. Darviri, A. Kattamis, 2020, Palliative and Supportive Care.

Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM

David T. W. Jones, T. Holland-Letz, F. Westermann, 2022, npj Precision Oncology.

Therapeutic perspective for children and young adults living with thalassemia and sickle cell disease

M. Cappellini, A. Kattamis, I. Motta, 2023, European Journal of Pediatrics.

Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in β-Thalassemia with Luspatercept: Longitudinal Results of the Believe Trial

M. Cappellini, V. Viprakasit, T. Coates, 2020 .

Efficacy and Safety of Deferasirox (Exjade®) in Reducing Cardiac Iron in Patients with β-Thalassemia Major: Results from the Cardiac Substudy of the EPIC Trial

D. Pennell, M. Cappellini, Chi-kong Li, 2008 .

Efficacy and Safety of Deferasirox (Exjade®) with up to 4.5 Years of Treatment in Patients with Thalassemia Major: A Pooled Analysis

M. Cappellini, R. Galanello, A. Piga, 2008 .

Deferasirox (Exjade®) in Pediatric Patients with β-Thalassemia: Update of 4.7-Year Efficacy and Safety from Extension Studies

R. Galanello, A. Piga, G. Forni, 2008 .

Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia

A. Shields, M. Cappellini, V. Viprakasit, 2023, BMJ open.

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients

Vip Viprakasit, Ali T Taher, Dany Habr, 2013, American journal of hematology.

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)

S. Perrotta, M. Cappellini, V. Viprakasit, 2013 .

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

M. Cappellini, V. Viprakasit, R. Galanello, 2012 .

Reduction in liver iron concentration is consistent across subgroups of non-transfusion-dependent thalassemia patients treated with deferasirox : results from the 1-year thalassa study

V. Viprakasit, R. Galanello, A. Taher, 2012 .

Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Amanda M Li, S. Sheth, M. Cappellini, 2022, Blood.

DEEP2 Trial – Key Findings in Paediatric Patients with Transfusion-dependent Thalassaemia

A. Kattamis, 2019, European Oncology & Haematology.

Combined Therapy with Deferoxamine and Deferiprone

A. Kattamis, 2005, Annals of the New York Academy of Sciences.

An open‐label, multicenter, efficacy, and safety study of deferasirox in iron‐overloaded patients with non‐transfusion‐dependent thalassemia (THETIS): 5‐year results

M. Cappellini, V. Viprakasit, A. Taher, 2022, American journal of hematology.

SERUM FERRITIN FOR PREDICTING CLINICALLY RELEVANT LIC THRESHOLDS TO GUIDE MANAGEMENT OF PATIENTS WITH NONTRANSFUSION-DEPENDENT THALASSEMIA TREATED WITH DEFERASIROX: THALASSA STUDY EXTENSION ANALYSIS

M. Cappellini, V. Viprakasit, R. Galanello, 2013 .

Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study

M. Cappellini, V. Viprakasit, R. Galanello, 2011 .

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

S. Perrotta, M. Cappellini, V. Viprakasit, 2019, Blood.

Quality of life in patients with β‐thalassemia: A prospective study of transfusion‐dependent and non‐transfusion‐dependent patients in Greece, Italy, Lebanon, and Thailand

M. Cappellini, V. Viprakasit, A. Taher, 2019, American journal of hematology.

Revisiting the non‐transfusion‐dependent (NTDT) vs. transfusion‐dependent (TDT) thalassemia classification 10 years later

S. Rivella, M. Cappellini, V. Viprakasit, 2020 .

Continued Improvement and Normalization of Myocardial T2* In Patients with β-thalassemia Major Treated with Deferasirox (Exjade®) for up to 3 Years

D. Pennell, M. Cappellini, Chi-kong Li, 2010 .

Efficacy and Safety of Once-Daily, Oral Iron Chelator Deferasirox (Exjade ® ) in a Large Group of Regularly Transfused Patients with β-Thalassemia Major

M. Cappellini, A. Taher, Mohsen Saleh Elalfy, 2008 .

Summary of Long-Term Renal Safety Data in Transfused Patients with Secondary Iron Overload Receiving Deferasirox (Exjade®, ICL670).

J. Ford, E. Glimm, C. Ponticelli, 2006 .

CONTINUED IMPROVEMENT IN CARDIAC T2*WITH DEFERASIROX TREATMENT OVER 2 YEARS: RESULTS FROM THE EXTENSION OF EPIC CARDIAC SUBSTUDY IN BETA-THALASSAEMIA PATIENTS WITH MYOCARDIAL SIDEROSIS

D. Pennell, M. Cappellini, Chi-kong Li, 2010 .

Efficacy and Safety of Deferasirox (Exjade®) in β-Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study.

D. Pennell, M. Cappellini, Chi-kong Li, 2009 .

Efficacy and safety of deferasirox (Exjade®) in patients with β-thalassemia major treated for up to 5 years

S. Perrotta, M. Cappellini, A. Piga, 2009 .

New Film-Coated Tablet Formulation of Deferasirox Is Well Tolerated in Patients with Thalassemia or MDS: Results of the Randomized, Phase II E.C.L.I.P.S.E. Study

S. Perrotta, A. Taher, A. Kattamis, 2016 .

Left ventricular deformation mechanics over time in patients with thalassemia major with and without iron overload

S. Adamopoulos, S. Kyrzopoulos, A. Kattamis, 2021, BMC Cardiovascular Disorders.

Randomized Phase II Study Evaluating the Efficacy and Safety of Deferasirox in Non-Transfusion-Dependent Thalassemia Patients with Iron Overload.

M. Cappellini, V. Viprakasit, A. Taher, 2009 .

Management of luspatercept therapy in patients with transfusion‐dependent β‐thalassaemia

S. Sheth, M. Cappellini, T. Coates, 2023, British journal of haematology.

Genotypic and Clinical Analysis of a Thalassemia Major Cohort: An Observational Study.

I. Papassotiriou, G. Chrousos, G. Lambrou, 2021, Advances in experimental medicine and biology.

The Effect of Treatment and Bone Metabolic Factors on Fracture Incidence in Patients with Thalassemia-Induced Osteoporosis: An Observational Study

G. Chrousos, G. Lambrou, E. Vlachou, 2020 .

Successful management of a small infant with Kasabach-Merritt phenomenon using vincristine: a case report.

M. Economou, A. Kattamis, F. Papachristou, 2014, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Summary of Joint European Hematology Association (EHA) and EuroBloodNet Recommendations on Diagnosis and Treatment of Methemoglobinemia

A. Iolascon, A. Kulozik, R. Russo, 2021, HemaSphere.

Investigation of FANCA mutations in Greek patients.

C. Sofocleous, S. Kitsiou, A. Kattamis, 2013, Anticancer research.

Telomere biology: from disorders to hematological diseases

E. Solomou, A. Kattamis, K. Roka, 2023, Frontiers in Oncology.

Cost-Utility Analysis of Pegaspargase for the Treatment of Acute Lymphoblastic Leukemia in Greece

G. Kourlaba, M. Bouzani, A. Kattamis, 2022, Clinical Drug Investigation.

Ischemic stroke in a pediatric patient with very rare coexistence of sickle-cell/β-thalassemia and neurofibromatosis type 1.

E. Rigatou, A. Kattamis, R. Pons, 2023, Pediatric blood & cancer.

Brachytherapy for pediatric patients at Gustave Roussy Cancer Campus: A model of international cooperation for highly specialized treatments.

C. Haie-meder, D. Orbach, S. Sarnacki, 2022, International journal of radiation oncology, biology, physics.

Dental caries and dental developmental defects as adverse effects of antineoplastic treatment in childhood cancer survivors

A. Polychronopoulou, A. Kattamis, K. Seremidi, 2023, European Archives of Paediatric Dentistry.

Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy

S. Sheth, M. Cappellini, A. Taher, 2023, Drug design, development and therapy.

Non-invasive myocardial iron assessment in thalassaemic patients. T2 relaxometry and magnetization transfer ratio measurements.

Nickolas Papanikolaou, A. Ghiatas, A. Kattamis, 2000, Acta radiologica.

Sickle cell disease landscape and challenges in the EU: the ERN-EuroBloodNet perspective.

P. Fenaux, F. Galactéros, Angelo Loris Brunetta, 2023, The Lancet. Haematology.

Expression analysis of NHEJ and HR genes in Ewing sarcomas: Indications of DSB repair dysfunction

M. Dimopoulos, K. Koutsoukos, K. Stefanaki, 2019, Annals of Oncology.

Isatuximab in Combination with Chemotherapy in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (ISAKIDS): Interim Analysis

A. Baruchel, G. Leverger, K. Yoo, 2021, Blood.

Fish evaluation of additional cytogenetic aberrations and hyperdiploidy in childhood Burkitt lymphoma

K. Stefanaki, G. Avgerinou, A. Kattamis, 2021, Leukemia & lymphoma.

Evidence that platelets from transfusion-dependent β-thalassemia patients induce T cell activation.

I. Papassotiriou, E. Solomou, A. Kattamis, 2022, Clinical immunology.

Immune response and adverse events after vaccination against SARS‐CoV‐2 in adult patients with transfusion‐dependent thalassaemia

M. Dimopoulos, I. Papassotiriou, I. Trougakos, 2022, British journal of haematology.

Characteristics of Café-au-lait Macules and their Association with the Neurofibromatosis type I Genotype in a Cohort of Greek Children

M. Tzetis, C. Kanaka-Gantenbein, A. Kattamis, 2023, Acta dermato-venereologica.

A Novel Variant in the TP53 Gene Causing Li–Fraumeni Syndrome

C. Stratakis, N. Iacovidou, P. Christopoulos, 2023, Children.

Real‐world complication burden and disease management paradigms in transfusion‐related β‐thalassaemia in Greece: Results from ULYSSES, an epidemiological, multicentre, retrospective cross‐sectional study

M. Diamantidis, E. Voskaridou, A. Kattamis, 2023, EJHaem.

Heterozygosity of the Complex Corfu δ0β+ Thalassemic Allele (HBD Deletion and HBB:c.92+5G>A) Revisited

J. Traeger-Synodinos, C. Vrettou, C. Sofocleous, 2022, Biology.

Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM.

David C. Jones, N. Jäger, S. Pfister, 2023, JCO precision oncology.

The Greek Registry of Shwachman Diamond‐Syndrome: Molecular and clinical data

M. Economou, C. Sofocleous, A. Kattamis, 2017, Pediatric Blood & Cancer.

The presurgical management with erythrocytapheresis of a patient with a high‐oxygen‐affinity, unstable Hb variant (Hb Bryn Mawr)

P. Fortina, C. Manno, P. Larson, 1997, Transfusion.

Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.

D. Pennell, M. Cappellini, Chi-kong Li, 2010, Blood.

Cost-Utility Analysis of Pegaspargase for the Treatment of Acute Lymphoblastic Leukemia in Greece

G. Kourlaba, M. Bouzani, A. Kattamis, 2022, Clinical Drug Investigation.

New-onset aplastic anemia after SARS-CoV-2 vaccination

E. Solomou, A. Kattamis, Elena Chatzikalil, 2023, International Journal of Hematology.

The Diverse Genomic Landscape of Diamond–Blackfan Anemia: Two Novel Variants and a Mini-Review

I. Kyriakidis, C. Sofocleous, A. Kattamis, 2023, Children.

Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease.

R. Redon, K. Schwarz, S. Knight, 2018, Blood.

Survival in a large cohort of Greek patients with transfusion‐dependent beta thalassaemia and mortality ratios compared to the general population

A. Kattamis, G. Chouliaras, C. Fragodimitri, 2011, European journal of haematology.

Venetoclax Combination Treatment of Acute Myeloid Leukemia in Adolescents and Young Adult Patients

Efthymia G. Rigatou, E. Solomou, A. Kattamis, 2024, Journal of clinical medicine.

Increased age-associated B cells in patients with acquired aplastic anemia correlate with IFN-γ

A. Symeonidis, N. Giannakoulas, P. Kollia, 2023, Blood advances.

Recommendations for diagnosis, treatment, and prevention of iron deficiency and iron deficiency anemia

A. Iolascon, L. De Franceschi, I. Andolfo, 2024, HemaSphere.

Longitudinal evaluation of eltrombopag in paediatric acquired severe aplastic anaemia

E. Solomou, G. Avgerinou, A. Kattamis, 2020, British journal of haematology.

National registry of hemoglobinopathies in Greece: updated demographics, current trends in affected births, and causes of mortality

I. Papassotiriou, M. Economou, M. Papadopoulou, 2018, Annals of Hematology.

Current approach to iron chelation in children

V. Viprakasit, A. Kattamis, Y. Aydinok, 2014, British journal of haematology.

Efﬁcacy of deferasirox in reducing and preventing cardiac iron overload in (cid:1) -thalassemia

D. Pennell, M. Cappellini, V. Viprakasit, 2010 .

Efﬁcacy of deferasirox in reducing and preventing cardiac iron overload in (cid:1) -thalassemia

D. Pennell, M. Cappellini, V. Viprakasit, 2010 .

Hb Souli, a 6 bp In-Frame Deletion on the HBA2 Gene (HBA2: c.[41-46delCCTGGG]) Leads to α-Thalassemia Intermedia, When in Trans to a Single α-Globin Gene Deletion

I. Papassotiriou, J. Traeger-Synodinos, E. Kanavakis, 2015, Hemoglobin.

LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients.

David C. Jones, S. Pfister, A. von Deimling, 2023, Neuro-oncology.

Antibody persistence 5 years after a 13-valent pneumococcal conjugate vaccine in asplenic patients with β-thalassemia: assessing the need for booster

A. Kattamis, V. Spoulou, Theano Lagousi, 2019, Annals of Hematology.